Reduced ability to concentrate and memory disorders of a degenerative or vascular nature, especially in the elderly.
active substance: pramiracetam;
1 film-coated tablet contains pramiracetam sulfate 818.4 mg, which corresponds to pramiracetam 600 mg;
Excipients: microcrystalline cellulose, colloidal anhydrous silica, crospovidone, calcium stearate, hydroxypropylcellulose, titanium dioxide (E 171), hypromellose, polyethylene glycol 3350, polyethylene glycol 400.
Pramistar is a nootropic drug that improves memory and learning ability. Its mechanism of action is not fully understood. By acting on cholinergic receptors and choline metabolism, pramiracetam stimulates neuronal activity. The drug does not have a depressant effect on the central and has no effect on the autonomic nervous system. Pramistar also has an antidepressant effect. During clinical trials in patients with senile dementia, mild to moderate pramiracetam increased concentration, improved learning, memory, orientation, and other mental activity.
Decreased ability to concentrate and memory disorders of degenerative or vascular nature, especially in the elderly.
Hypersensitivity to the active substance or to any of the excipients. Hemorrhage in the brain. Severe renal failure. Hepatic failure.
Use during pregnancy or breastfeeding
Pramiracetam is contraindicated during pregnancy or breastfeeding; there are no sufficient data from use during pregnancy or lactation.
Method of application and dosage
The recommended dose is 600 mg every 12 hours.
The total daily dose should not exceed 1200 mg per day.
A clinically significant effect is achieved within 4-8 weeks of treatment. In the case of long-term treatment in elderly patients, creatinine levels should be checked regularly.
Patients with renal failure.
Delayed excretion of pramiracetam is observed in patients with renal insufficiency. The clinical significance of delayed excretion of pramiracetam in renal insufficiency from mild to moderate severity has not been determined. Therefore, caution should be exercised when treating patients with mild to moderate renal insufficiency, and Pramistar should be discontinued if side effects occur, as this may be a sign of accumulation of the active substance in the body. Pramistar is contraindicated in severe renal insufficiency (see section “Contraindications”).
Studies in children have not been performed, so the drug is not recommended for use in children.
There are no reports of overdose.
- Metabolism and nutrition disorders: loss of appetite;
- Mental disorders: agitation, insomnia, confusion, dysphoria;
- Nervous system disorders: dizziness, tremor;
- Disorders of the gastrointestinal tract: nausea, upper abdominal pain, dry mouth, dyspepsia, incontinence;
- Musculoskeletal and connective tissue disorders: muscle spasms;
- Disorders of the kidneys and urinary tract: urinary incontinence.
Do not use the drug after the expiration date indicated on the package.
Store at a temperature not exceeding 30 ºC. Keep the medicine out of the reach of children.